Abbott Laboratories (ABT)
NYSE: ABT
· Real-Time Price · USD
131.78
2.50 (1.93%)
At close: Aug 15, 2025, 3:10 PM
Abbott Laboratories Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | 1.32B | 9.23B | 1.65B | 1.3B | 1.23B | 1.59B | 1.44B | 1.38B | 1.32B | 1.03B | 1.44B | 2.02B | 2.45B | 1.99B | 2.1B | 1.19B | 1.79B |
Depreciation & Amortization | 756M | 807M | 801M | 805M | 805M | 813M | 824M | 800M | 806M | 807M | 815M | 822M | 823M | 883M | 847M | 874M | 934M |
Stock-Based Compensation | 289M | 111M | 117M | 141M | 304M | 114M | 117M | 132M | 281M | 115M | 123M | 142M | 305M | 106M | 114M | 132M | 288M |
Other Working Capital | n/a | -8.47B | n/a | n/a | n/a | -1.89B | -179M | -660M | -1.08B | -38M | 71M | 92M | -205M | -1.22B | -37M | -97M | 9.36B |
Other Non-Cash Items | -436M | 1.11B | -22M | 140M | -748M | 2.04B | -179M | -660M | n/a | 257M | 71M | n/a | n/a | 195M | n/a | n/a | -6M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | -517M | -8.39B | 163M | -428M | -561M | -1.52B | -321M | -444M | -1.26B | 114M | 336M | -572M | -1.51B | -106M | -360M | -67M | -372M |
Operating Cash Flow | 1.42B | 2.87B | 2.71B | 1.96B | 1.02B | 3.04B | 1.88B | 1.2B | 1.14B | 2.33B | 2.78B | 2.41B | 2.06B | 3.07B | 2.7B | 2.13B | 2.64B |
Capital Expenditures | -484M | -720M | -556M | -533M | -398M | -755M | -560M | -507M | -380M | -610M | -467M | -379M | -321M | -614M | -461M | -413M | -397M |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | -51M | -786M | n/a | n/a | n/a | 48M | n/a | -134M | -86M | 48M | -15M |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | -114M | -38M | 79M | -86M | n/a | -3M | 41M | -41M | -173M | -27M | 14M | -14M |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | 43M | 38M | 707M | n/a | n/a | n/a | n/a | n/a | 77M | -81M | 81M | n/a |
Other Investing Acitivies | 14M | -146M | -38M | 80M | -27M | 2M | -23M | -706M | 4M | -22M | -14M | 26M | 2M | 173M | 4M | 6M | 4M |
Investing Cash Flow | -470M | -866M | -594M | -453M | -425M | -824M | -634M | -1.21B | -462M | -632M | -484M | -264M | -360M | -671M | -651M | -264M | -422M |
Debt Repayment | -1.04B | -613M | 43M | 160M | -127M | -939M | -1.51B | 12M | -42M | 10M | 24M | 10M | -743M | -196M | -67M | -7M | 22M |
Common Stock Repurchased | -280M | -315M | -751M | -3M | -226M | -259M | -2M | -426M | -540M | -685M | -798M | -5M | -2.31B | -974M | -579M | -471M | -275M |
Dividend Paid | -1.03B | -958M | -960M | -961M | -957M | -888M | -888M | -890M | -890M | -823M | -826M | -828M | -832M | -798M | -801M | -803M | -800M |
Other Financial Acitivies | 287M | 25M | 92M | 13M | 134M | 34M | 56M | 15M | 62M | 41M | 57M | 10M | 59M | 82M | 70M | 17M | 86M |
Financial Cash Flow | -2.06B | -1.86B | -1.58B | -791M | -1.18B | -2.05B | -2.34B | -1.29B | -1.41B | -1.46B | -1.54B | -813M | -3.82B | -1.89B | -1.38B | -1.26B | -967M |
Net Cash Flow | -1.08B | 58M | 571M | 703M | -612M | 187M | -1.13B | -1.33B | -721M | 288M | 657M | 1.26B | -2.12B | 497M | 644M | 604M | 1.22B |
Free Cash Flow | 933M | 2.15B | 2.15B | 1.43B | 627M | 2.28B | 1.32B | 696M | 763M | 1.72B | 2.31B | 2.03B | 1.74B | 2.45B | 2.24B | 1.72B | 2.24B |